US 6,221,608 B1Granted

Methods for identifying erythropoietin receptor binding protein

AssigneeOrtho Pharmaceutical Corporation

InventorsSteven A. Middleton, Dana Johnson, Frank J. McMahon, Linda S. Mulkahy, Linda K. Jolliffe

Life of this patent

Estimating the term…

Loading patent…

Abstract

The extracellular domain of the human erythropoietin receptor (EPO binding protein, EBP) has been expressed and overproduced in E. coli. Control of oxygen levels and pH during high density fermentation allows the production of only the protein variant with the native amino terminus. Methods disclosed permit the efficient recovery of purified EBP which quantitatively binds EPO. The active purified protein competes with membrane associated EPO receptor for binding [125I]EPO and neutralizes EPO dependent stimulation in a cell based proliferation assay. Further, the radioligand equilibrium binding constant for this interaction has been determined by immobilizing EBP on agarose gel via a free cysteine. The EBP of the present invention has many uses including the structural determination of the protein by NMR or crystallography, in drug design and discovery, and as a therapeutic. A fusion protein of EBP and an immunoglobulin heavy chain was also produced. This protein, termed EBP-Ig, is a preformed dimerization template and is also useful in drug design and discovery methods.

Claims1

Dependent claims

A method of identifying a modulator that dimerizes a receptor, comprising the steps:

(a) combining a known concentration of a compound suspected of being a modulator and a known concentration of a receptor-dimerizing ligand which is labeled, wherein said ligand is capable of binding a preformed dimerization template, with a preformed dimerization template, wherein said preformed dimerization template comprises a ligand binding domain of an erythropoietin receptor;
(b) measuring competitive binding of said suspected modulator and said ligand to said preformed dimerization template by quantifying the amount of bound ligand, wherein a lower amount of bound ligand in the presence compared to the absence of said suspected modulator indicates binding of said suspected modulator to said preformed dimerization template;
(c) combining the modulator of step (b) that binds to said preformed dimerization template with cells that proliferate in response to said ligand binding to said cells;
and
(d) measuring the proliferation of said cells in the presence of said modulator,
wherein an increase in proliferation in the presence of said modulator indicates formation of a dimerized receptor.

3 more elements

Dependencies are inferred from the claim text.